Updated ASCIA article on oral immunotherapy (OIT) for food allergy
24 May 2019:
ASCIA has updated its information on oral immunotherapy (OIT) for food allergy to include information from a meta-analysis (a method to combine data from multiple studies) of 12 OIT trials. This meta-analysis was published in the Lancet journal in April 2019 and is the most comprehensive and rigorous review of OIT for peanut allergy to date. OIT for food allergy is an emerging experimental treatment, and its benefits and harms are still being studied in clinical trials globally. The updated ASCIA article is available at:
Recent Lancet publication is a comprehensive review of OIT for peanut allergy
A meta-analysis that combined data from 12 OIT trials was published in the Lancet journal in April 2019. This is the most comprehensive and rigorous review of OIT for peanut allergy to date. It reviewed the effectiveness and safety of OIT for peanut versus placebo (in OIT study but in the group that was not given peanut) or peanut avoidance (patients not in OIT study).
Results showed that whilst OIT can achieve the goal of desensitisation for many people, those receiving OIT had more frequent allergic reactions, including anaphylaxis. They also required more frequent treatment with adrenaline (epinephrine) autoinjectors (such as EpiPen) than those who avoided peanut and did not receive OIT.
The Lancet publication supports the need for improved food allergy treatment approaches with an enhanced safety profile and trials focused on patient-important outcomes. ASCIA also supports this approach.
The abstract of the Lancet publication is available at: